About Volition
Volition is a company based in Gembloux (Belgium) founded in 1995. It operates as a HealthTech and Professional Services. The company has 85 employees. Volition has completed 1 acquisition, including Octamer. Volition offers products and services including Nu.Q® NETs, Nu.Q® Vet Cancer Test, Nu.Q® Discover, and Nu.Q® Cancer. Volition operates in a competitive market with competitors including Guardant Health, GRAIL, Color, Delfi Diagnostics and BillionToOne, among others.
- Headquarter Gembloux, Belgium
- Employees 85
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website volition.com
- Social LinkedIn X Facebook
- Legal Name Volitionrx Limited
Products & Services of Volition
Volition offers a comprehensive portfolio of products and services, including Nu.Q® NETs, Nu.Q® Vet Cancer Test, Nu.Q® Discover, and Nu.Q® Cancer.
A CE-marked test for detecting NETosis in patients.
Blood test for detecting cancer in dogs affordably.
Assays for epigenetic profiling in drug development studies.
Blood-based assays for cancer detection and beyond.
Funding Insights of Volition
- Total Rounds 13
- Last Round Post-IPO — $2.32M
- First Round $1.2M
(Jul 2012)
- Investors Count 3
Latest 10 of 13 funding rounds of Volition with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2026 | $2.32M | Post-IPO | – | – | |
| May 2025 | $16.25M | Post-IPO | – | – | – |
| Mar 2024 | $100,000 | Post-IPO | – | – | – |
| Dec 2023 | $5.43M | Post-IPO | – | – | |
| Jan 2021 | $1.3M | Grant | – | – | |
| Nov 2014 | $721,849 | Post-IPO | – | – | – |
| Oct 2014 | $229,393 | Post-IPO | – | – | – |
| Sep 2014 | $750,000 | Post-IPO | – | – | – |
| Sep 2014 | $1.19M | Post-IPO | – | – | – |
| Mar 2014 | $3M | Post-IPO | – | – | – |
3 investors in total: 3 institutional.
Investors in Volition
Volition has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Belgium, Wallonie Entreprendre and Namur Invest.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | wallonie-entreprendre.be | - | |
Official Belgian government information and services are provided online. | 1830 | belgium.be | Brussels, Belgium | |
- | – | namurinvest.be | - |
Investor details for Volition
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Volition
48 people are tracked at Volition (18 in leadership, 7 in board & advisors, 23 in team); the tracked headcount is 85.
| Name | Role | Group |
|---|---|---|
Cameron Reynolds | CEO | Leadership |
Priscilla van Den Ackerveken | Head Of Translational Science Unit | Leadership |
Mitchell Aicher | Director Of Operations And Clinical Development | Leadership |
Jason Terrell M.D. | Chief Executive Officer Of Volition America | Leadership |
Louise Batchelor | Group Chief Marketing & Communications Officer | Leadership |
Gael Forterre | Chief Commercial Officer (cco) | Leadership |
M'Hammed Bougoussa | Industrialization And Production Director | Leadership |
Jasmine K. | Chief Executive Officer, Singapore Volition | Leadership |
Terig Hughes | Chief Financial Officer | Leadership |
Simin Kayhan | Director Of Fp&a | Leadership |
Alexandra Thompson | International HR Director | Leadership |
Gaetan Michel | Chief Operating Officer | Leadership |
Marielle Herzog | R&d Director - Belgian Volition | Leadership |
Terry Kelly | Chief Innovation Officer, Volition Rx | Leadership |
Sheila Shah | Associate Director, Quality | Leadership |
Msc Remi Rabeuf | Vice President Corporate Alliances & Strategic Partnerships | Leadership |
Emmanuel Demillecamps | Head Of Business Development | Leadership |
Romuald Laurenti | Associate Director, Group Legal | Leadership |
Martin C Faulkes | Chairman | Board & advisors |
Alan Colman | Non-Executive Director | Board & advisors |
28 more people are available in the full profile.
Complete people profiles for Volition
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Volition
Volition is a publicly listed company on the AMEX with ticker symbol VNRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date06 Feb 2015
- Listed onNYSE: VNRX
- Listed entityVolitionRX Limited
- Exchange sectorHealth technology
Investments & Acquisitions by Volition
Volition has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Octamer.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provider of screening substrates for epigenetics research | octamer.de | Grafelfing, Germany | 2018 | Dec 2019 | $722,626 |
Complete acquisition details for Volition
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Volition
5 dated milestones of Volition across 31 years, from founding to its latest funding, stage changes and deals.
- Founded Volition is founded.
- Funding First funding round of $1.2M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Octamer.
- Funding Latest funding round, Post-IPO, of $2.3M.
Competitors of Volition
Volition operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Color, Delfi Diagnostics and BillionToOne, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| grail.com | 2016 | Menlo Park, United States | $3.22B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| color.com | 2013 | Burlingame, United States | $506.44M | 687 | Cancer care is delivered through a virtual clinic by Color. | |
| delfidiagnostics.com | 2019 | Baltimore, United States | $331.59M | – | Provider of DNA sequencing for cancer detection | |
| billiontoone.com | 2015 | San Francisco, United States | $388.62M | 47 | Provider of cell-free cancer liquid biopsy test | |
| thrivedetect.com | 2019 | Cambridge, United States | $367M | 138 | Blood-based liquid biopsy tests for multiple cancer detection are provided. | |
| earli.com | 2018 | San Francisco, United States | $40M | 38 | Early cancer detection tests are developed using synthetic biomarkers. | |
| nucleix.com | 2008 | Rehovot, Israel | $85.5M | – | Non-invasive molecular diagnostic tests for cancer are developed using epigenetics. | |
| raindancetech.com | 2004 | Billerica, United States | $111.66M | 105 | Developer of nucleic acid detection and quantification systems |
Detailed competitors of Volition
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Volition
The website of Volition (volition.com) receives about 12.9K visits a month.
- Monthly visits12.9K
▲ 5.8% vs previous month
Websites whose visitors overlap most with Volition. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| govolition.com | 100% | 29.7K | #930,104 | View details | |
| sassieshop.com | 92% | – | #55,280 | View details | |
mysteryshop.org | mysteryshop.org | 86% | – | – | – |
jobslinger.com | jobslinger.com | 77% | – | #435,688 | – |
| realtor.com | 57% | 110M | #330 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for Volition
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Volition
Complete news archive for Volition
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Volition
10 companies that operate in the same segment as Volition (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Volition
Volition was founded in 1995 and raised its 1st funding round 17 years after it was founded.
Volition is headquartered in Gembloux, Belgium. It is registered at Gembloux, Namur, Belgium.
Cameron Reynolds is the current CEO of Volition.
Volition has 85 employees.
Annual revenue of Volition is $1.73M as on Dec 31, 2025.
Volition is engaged in advancing the science of epigenetics to revolutionize the diagnosis and monitoring of life-altering diseases such as cancer and sepsis. The company develops blood-based diagnostic tests using its proprietary Nu.Q technology, which detects characteristic epigenetic changes in nucleosomes from the earliest disease stages. Solutions are offered for human health, including NETosis detection, and veterinary applications like cancer screening in dogs. Additionally, research assays under the Nu.Q Discover program support drug development and clinical studies. Operating across multiple sectors, Volition collaborates globally with academic institutions and pharmaceutical companies from its offices in the USA, UK, Belgium, and Singapore.
Volition's top competitors include Guardant Health, GRAIL and BillionToOne.
Volition offers Nu.Q® NETs, Nu.Q® Vet Cancer Test, Nu.Q® Discover, and Nu.Q® Cancer.
Yes, Volition is publicly traded on AMEX under the ticker symbol VNRX.
Volition has made 1 acquisition, including Octamer.
Volition has 3 investors. Key investors include Belgium, Wallonie Entreprendre, and Namur Invest.
Volition operates through Volitionrx Limited.